EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 151 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $455,453 | -18.9% | 28,881 | +0.0% | 0.00% | 0.0% |
| Q2 2023 | $561,427 | +6.6% | 28,880 | +55.5% | 0.00% | 0.0% |
| Q1 2023 | $526,888 | -37.0% | 18,572 | -35.1% | 0.00% | 0.0% |
| Q4 2022 | $836,475 | +26.4% | 28,617 | +14.3% | 0.00% | 0.0% |
| Q3 2022 | $662,000 | -29.5% | 25,045 | +18.5% | 0.00% | 0.0% |
| Q2 2022 | $939,000 | -1.7% | 21,135 | -2.3% | 0.00% | 0.0% |
| Q1 2022 | $955,000 | -24.1% | 21,631 | -12.4% | 0.00% | 0.0% |
| Q4 2021 | $1,258,000 | +19.5% | 24,705 | +30.8% | 0.00% | 0.0% |
| Q3 2021 | $1,053,000 | +159.4% | 18,883 | +99.3% | 0.00% | – |
| Q2 2021 | $406,000 | +56.8% | 9,475 | +52.4% | 0.00% | – |
| Q1 2021 | $259,000 | -2.6% | 6,216 | -0.6% | 0.00% | – |
| Q3 2020 | $266,000 | -16.6% | 6,255 | -6.0% | 0.00% | – |
| Q2 2020 | $319,000 | -55.1% | 6,655 | -56.9% | 0.00% | -100.0% |
| Q1 2020 | $710,000 | +2.0% | 15,452 | +33.4% | 0.00% | 0.0% |
| Q4 2019 | $696,000 | +82.2% | 11,586 | +71.4% | 0.00% | – |
| Q3 2019 | $382,000 | +297.9% | 6,758 | +291.8% | 0.00% | – |
| Q2 2019 | $96,000 | -59.8% | 1,725 | -63.5% | 0.00% | -100.0% |
| Q1 2019 | $239,000 | +22.6% | 4,727 | -2.2% | 0.00% | – |
| Q4 2018 | $195,000 | -99.4% | 4,831 | -99.1% | 0.00% | -100.0% |
| Q3 2018 | $35,452,000 | -29.7% | 511,350 | -23.3% | 0.07% | -31.8% |
| Q2 2018 | $50,430,000 | -6.0% | 666,534 | -34.6% | 0.11% | -8.5% |
| Q1 2018 | $53,674,000 | -4.3% | 1,018,683 | -3.0% | 0.12% | -0.8% |
| Q4 2017 | $56,101,000 | -3.8% | 1,050,167 | +7.4% | 0.12% | -9.9% |
| Q3 2017 | $58,325,000 | -23.7% | 977,950 | +1.0% | 0.13% | -26.8% |
| Q2 2017 | $76,395,000 | -14.1% | 968,379 | -9.7% | 0.18% | -15.6% |
| Q1 2017 | $88,971,000 | +29.9% | 1,072,714 | +24.3% | 0.21% | +22.5% |
| Q4 2016 | $68,495,000 | +41.8% | 863,316 | +25.1% | 0.17% | +28.1% |
| Q3 2016 | $48,318,000 | – | 690,260 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JW Asset Management, LLC | 475,755 | $25,068,000 | 24.71% |
| Hudson Executive Capital LP | 971,000 | $51,162,000 | 15.09% |
| Park West Asset Management LLC | 1,051,274 | $55,392,000 | 2.47% |
| U S GLOBAL INVESTORS INC | 19,200 | $1,012,000 | 0.62% |
| Capital Impact Advisors, LLC | 26,317 | $1,387,000 | 0.57% |
| CLARK ESTATES INC/NY | 56,278 | $2,965,000 | 0.47% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 873,131 | $46,005,000 | 0.41% |
| ProQuest Associates IV LLC | 6,777 | $357,000 | 0.41% |
| Granite Investment Partners, LLC | 114,207 | $6,017,000 | 0.40% |
| GLOBEFLEX CAPITAL L P | 30,900 | $1,628,000 | 0.34% |